The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor

Molecular Pharmacology

Volumn 67, Issue 5, 2005, Pages 1714-1722

  Fagart, Jérôme ^a   Seguin, Cendrine ^a   Pinon, Grégory Maurice ^a   Rafestin Oblin, Marie Edith ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA PROPYLSPIRONOLACTONE; ACETIC ACID DERIVATIVE; ALANINE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CANRENONE; DEOXYCORTICOSTERONE; EPLERENONE; HYDROCORTISONE; METHIONINE; MEXRENONE; MINERALOCORTICOID RECEPTOR; MUTANT PROTEIN; PROGESTERONE; PROPANE; SPIRONOLACTONE; STEROID;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESSENTIAL HYPERTENSION; GENETIC TRANSFECTION; IC 50; IN VITRO STUDY; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; STEREOSPECIFICITY; STRUCTURE ANALYSIS; TRANSCRIPTION TERMINATION; WILD TYPE;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; METHIONINE; MICE; PROTEIN BINDING; RABBITS; RECEPTORS, MINERALOCORTICOID;

EID: 17844388558     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.010710     Document Type: Article

References (39)

1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, and Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science (Wash DC) 237:268-275.
2. Auzou G, Fagart J, Souque A, Hellal-Levy C, Wurtz JM, Moras D, and ME Rafestin-Oblin (2000) A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones. Mol Pharmacol 58:684-691.
3. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105.
4. Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin ME, and Farman N (2003) Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity. J Steroid Biochem Mol Biol 84:239-244.
5. Bourguet W, Andry V, Iltis C, Klaholz B, Potier N, Van Dorsselaer A, Chambon P, Gronemeyer H, and Moras D (2000) Heterodimeric complex of RAR and RXR nuclear receptor ligand-binding domains: purification, crystallization and preliminary X-ray diffraction analysis. Protein Expr Purif 19:284-288.
6. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
7. Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, and Corvol P (1979) Mechanism of action of a new antialdosterone compound, prorenone. Endocrinology 104:1194-1200.
8. Corvol P, Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, and Menard J (1978) Spirolactones: clinical and pharmacologic studies. Adv Nephrol Necker Hosp 7:199-215.
9. Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, and Rafestin-Oblin ME (1996) Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem J 315:421-427.
10. Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou G, and Rafestin-Oblin ME (1998) Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor. Mol Endocrinol 12:855-863.
11. de Wet JR, Wood KV, DeLuca M, Helinski DR, and Subramani S (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7:725-737.
12. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science (Wash DC) 240:889-895.
13. Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, and Rafestin-Oblin ME (1998) Antagonism in the human mineralocorticoid receptor. EMBO (Eur Mol Biol Organ) J 17:3317-3325.
14. Farman N and Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol 280:F181-F192.
15. Fejes-Toth G, Pearce D, and Naray-Fejes-Toth A (1998) Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA 95:2973-2978.
16. Fuse H, Kitagawa H, and Kato S (2000) Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol Endocrinol 14:889-899.
17. Gittler RD and Fajans SS (1995) Primary aldosteronism (Conn's syndrome). J Clin Endocrinol Metab 80:3438-3441.
18. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, and Klemm SA (1993) Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20:296-298.
19. Gouilleux F, Sola B, Couette B, and Richard-Foy H (1991) Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter. Nucleic Acids Res 19:1563-1569.
20. Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, and Rafestin-Oblin ME (2000) Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol Endocrinol 14:1210-1221.
21. Herbomel P, Bourachot B, and Yaniv M (1984) Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 39:653-662.
22. Liu W, Wang J, Yu G, and Pearce D (1996) Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Mol Endocrinol 10:1399-1406.
23. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, and Chambon P (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839.
24. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171.
25. McMahon EG (2003) Eplerenone, a new selective aldosterone blocker. Curr Pharm Des 9:1065-1075.
26. Moras D and Gronemeyer H (1998) The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391.
27. Nakao R, Haji M, Yanase T, Ogo A, Takayanagi R, Katsube T, Fukumaki Y, and Nawata H (1992) A single amino acid substitution (Met786-Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome. J Clin Endocrinol Metab 74:1152-1157.
28. Nemoto T, Ohara-Nemoto Y, Sato N, and Ota M (1993) Dual roles of 90-kDa heat shock protein in the function of the mineralocorticoid receptor. J Biochem (Tokyo) 113:769-775.
29. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, and Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321.
30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717.
31. Pratt WB and Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360.
32. Rafestin-Oblin ME, Couette B, Radanyi C, Lombes M, and Baulieu EE (1989) Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation. J Biol Chem 264:9304-9309.
33. Rogerson FM and Fuller PJ (2003) Interdomain interactions in the mineralocorticoid receptor. Mol Cell Endocrinol 200:45-55.
34. Rupprecht R, Arriza JL, Spengler D, Reul JM, Evans RM, Holsboer F, and Damm K (1993) Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol 7:597-603.
35. Tallec LP, Kirsh O, Lecomte MC, Viengchareun S, Zennaro MC, Dejean A, and Lombes M (2003) Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 17:2529-2542.
36. Trapp T and Holsboer F (1995) Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215:286-291.
37. Weinberger MH, Roniker B, Krause SL, and Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15:709-716.
38. Williams SP and Sigler PB (1998) Atomic structure of progesterone complexed with its receptor. Nature (Lond) 393:392-396.
39. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, and Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94.